Integra LifeSciences Holdings Corporation (IART) News
Track canonical SquawkNews coverage tagged to IART, Integra LifeSciences Holdings Corporation. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 9 indexed stories across 4 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
IART Integra Lifesciences RESULTS: Q2, Q2 ADJ Net Income $43.7M, Q2 ADJ EPS $0.56 vs. EST $0.48, Q2 ADJ EBITDA $78.4M, Q2 EPS $0.06, Q2 REV
IART Integra Lifesciences RESULTS: Q2, Q2 ADJ Net Income $43.7M, Q2 ADJ EPS $0.56 vs. EST $0.48, Q2 ADJ EBITDA $78.4M, Q2 EPS $0.06, Q2 REV $418.8M vs. EST $418.6M, Integra Lifesciences Earnings Notes:, Integra Lifescien
EARNINGS | Jul 29, 2026, 10:24 AM UTC
L
Integra Lifesciences Affirms FY2026 Adj EPS Guidance of $2.40-$2.50 vs $2.45 Est; Lowers FY2026 Sales Guidance from $1.662B-$1.702B to $1.65
Integra Lifesciences (NASDAQ: IART ) affirms FY2026 Adj EPS guidance from $2.40-$2.50 to $2.40-$2.50 vs $2.45 analyst estimate. Lowers FY2026 sales outlook from $1.662 billion-$1.702 billion to $1.654 billion-$1.695 bill
EARNINGS | Jul 29, 2026, 10:08 AM UTC
L
IART - Integra LifeSciences Reports Second Quarter 2026 Financial Results
IART - Integra LifeSciences Reports Second Quarter 2026 Financial Results
EARNINGS | Jul 29, 2026, 10:00 AM UTC
L
IART new Neutral W/ $19 PT @ UBS
IART new Neutral W/ $19 PT @ UBS
EQUITY | Jul 28, 2026, 12:46 PM UTC
L
IART Initiated Neutral W/$19.00 PT at UBS
IART Initiated Neutral W/$19.00 PT at UBS
EQUITY | Jul 28, 2026, 11:49 AM UTC
L
Top Initiations: ATEC BDX BLCO EW SGHT SIBN STE ZBH: BUY @ UBS COO GKOS GMED IART RXST TFX TMDX: NEUTRAL @ UBS INSP STAA: SELL @ UBS BNTC: O
Top Initiations: ATEC BDX BLCO EW SGHT SIBN STE ZBH: BUY @ UBS COO GKOS GMED IART RXST TFX TMDX: NEUTRAL @ UBS INSP STAA: SELL @ UBS BNTC: OUTPERFORM @ Wedbush CRWD: BUY @ Loop FTH: OUTPERFORM @ Opp HRB: EQUAL WEIGHT @ S
EQUITY | Jul 28, 2026, 11:11 AM UTC
H
BMO starts 'show-me story' Integra LifeSciences with a Market Perform
As previously reported, BMO Capital initiated coverage of Integra LifeSciences with a Market Perform rating and $19 price target. While early signs of recovery - including a Q1 beat and record Integra Skin production - a
EARNINGS | Jul 08, 2026, 08:34 PM UTC
H
Integra LifeSciences price target raised to $19 from $16 at Citi
Citi raised the firm's price target on Integra LifeSciences to $19 from $16 and keeps a Neutral rating on the shares. For Q2 earnings season, given "the skittish trading environment," the firm prefers higher-quality medt
EQUITY | Jul 08, 2026, 10:36 AM UTC
L
IART Appoints Executives
Integra LifeSciences announces key executive appointments to enhance commercial execution and customer engagement
EQUITY | Jun 23, 2026, 12:01 PM UTC